ABC Heart Fail Cardiomyop 2022; 2(1): 64-66
The EMPEROR-Preserved Trial: Results that Innovate the Treatment of Heart Failure with Preserved Ejection Fraction
Ricardo Mourilhe-Rocha
, Marcelo Imbroinise Bittencourt
, Felipe Neves de Albuquerque
, Ana Luiza Ferreira Salles
, Pedro Pimenta de Mello Spineti
, Denilson Campos de Albuquerque
The treatment of heart failure with reduced ejection fraction (HFrEF) has been improving by numerous pharmacological and non-pharmacological options, as described in national and international guidelines. However, in the scenario of patients with HF with preserved EF (HFpEF), no therapeutic update has occurred since the last published guideline. –
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective hypoglycemic agents in type 2 diabetes mellitus (T2DM) and are associated with improved glycemic control as well as with reduced body mass and blood pressure. In large-scale randomized trials of patients with diabetes, the use of SGLT2 inhibitors has improved cardiovascular and renal outcomes – including hospitalization for HF (HHF). This benefit was also observed in patients without diabetes who have HFrEF. That is, the presence of T2DM is not necessary to endorse the clinical benefit of SGLT2 inhibitors in HFrEF.
[…]
Keywords: Heart Failure; preserved ejection fraction; Treatment
395
